The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib

Oncologist

Volumn 16, Issue 9, 2011, Pages 1270-1279

  Yau, Thomas ^a   Yao, T J ^a   Chan, Pierre ^a   Wong, Hilda ^a   Pang, Roberta ^a   Fan, Sheung Tat ^a   Poon, Ronnie T P ^a  

^a QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

Alpha fetoprotein; Hepatocellular carcinoma; Sorafenib; Surrogate

Indexed keywords

ALANINE AMINOTRANSFERASE; ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; HEPATITIS B SURFACE ANTIGEN; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASCITES; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DISTANT METASTASIS; DRUG RESPONSE; FEMALE; HEPATITIS; HUMAN; LIVER CELL CARCINOMA; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; SEROLOGY; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; ALPHA-FETOPROTEINS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SURVIVAL ANALYSIS;

EID: 80053212846     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2011-0105     Document Type: Article

References (21)

1. Hussain SA, Ferry DR, El-Gazzaz G et al. Hepatocellular carcinoma. Ann Oncol 2001;12:161-172.
2. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocel-lular carcinoma. N Engl J Med 2008;359:378-390.
3. Cheng AL, Kang YK, Chen Z et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34.
4. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48. Geneva: WHO, 1979.
5. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92: 205-216.
6. Vora SR, Zheng H, Stadler ZK et al. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. The Oncologist 2009;14:717-725.
7. Choi BI, Lee JM. Advancement in HCC imaging: diagnosis, staging and treatment efficacy assessments: imaging diagnosis and staging of hepato-cellular carcinoma. J Hepatobiliary Pancreat Sci 2010;17:369-373.
8. Chan SL, Mo FK, Johnson PJ et al. New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 2009;27:446-452.
9. Abou-Alfa GK, Schwartz L, Ricci S et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006;24: 4293-4300.
10. Llovet JM, Di Bisceglie AM, Bruix J et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698-711.
11. Chen LT, Liu TW, Chao Y et al. Alpha-fetoprotein response predicts survival benefits of thalidomide in advanced hepatocellular carcinoma. Aliment Pharmacol Ther 2005;22:217-226.
12. Shao YY, Lin ZZ, Hsu C et al. Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma. Cancer 2010;116:4590-4596.
13. Yau T, Chan P, Ng KK et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 2009;115:428-436.
14. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
15. Collett D. Modelling survival data in medical research. Chapman & Hall/ CRC Texts in Statistical Science. Boca Raton, FL: CRC Press, 2003.
16. The PHREG Procedure; Variable Selection Methods. Cary, NC: SAS Institute Inc. Available at http://support.sas.com/documentation/cdl/en/statug/63347/HTML/default/viewer.htm#statug_phreg_sect001.htm, accessed 2009.
17. Lin DY, Wei LJ, Ying Z. Checking the Cox model with cumulative sums of martingale-based residuals. Biometrika 1993;80:557-572.
18. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med 2000;19:453-473.
19. NCCN Clinical Practice Guidelines in Oncology In Edition, 2010. Available at http://www.nccn.org/professionals/physician_gls/f_guidelines.asp, accessed 2010.
20. Riaz A, Ryu RK, Kulik LM et al. Alpha-Fetoprotein response after locore-gional therapy for hepatocellular carcinoma: oncologic marker of radio-logic response, progression, and survival. J Clin Oncol 2009;27:5734- 5742.
21. Tamura Y, Igarashi M, Suda T et al. Fucosylated fraction of alpha-fetopro-tein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment. Dig Dis Sci 2010;55:2095-2101.